DUBLIN, July 25, 2017 /PRNewswire/ --
The "Global Castration Resistant Prostate Cancer Treatment Market 2017-2021" report has been added to Research and Markets' offering.
The global castration-resistant prostate cancer treatment market to grow at a CAGR of 9.01% during the period 2017-2021.
Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
One trend in the market is increasing consolidation in cancer treatment market. The oncology drugs industry has seen significant R&D and funding, which are largely responsible for the increasing consolidation of the industry. The rising trend of movement of cancer treatment from clinics to hospitals signifies the growing importance of strategic alliances and acquisition among the vendors.
According to the report, one driver in the market is physician's preference toward hormonal therapy. The abnormal growth in testosterone level characterizes prostate cancer. Therefore, hormone therapies, which control the secretion of this hormone and help reduce the growth of prostate cancer cells, remain the most sought-after therapy for treating CRPC. The proven efficacious profiles of these therapies with established clinical credentials have led to increased adoption among physicians. Hormonal therapies dominate the global CRPC treatment market and are expected to continue with the same during the forecast period.
Further, the report states that one challenge in the market is high cost of treatment. The high cost of treatment is a major problem for the CRPC patients across the globe. Many of the treatment options available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. Virtual monopoly among the drug manufacturers and the high cost of R&D are some of the major factors for the high cost of CRPC treatment. A large proportion of population either skip the treatment or leave it in the middle.
- Astellas Pharma
- Johnson & Johnson
Other prominent vendors
- Active Biotech
- ANI Pharmaceuticals
- Bavarian Nordic
- Bristol-Myers Squibb
- Innocrin Pharmaceutical
- Myovant Sciences
- Northwest Biotherapeutics
- OncoGenex Pharmaceuticals
- Oncolytics Biotech
- Takeda Pharmaceutical
- Teva Pharmaceutical Industries
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Pipeline landscape
Part 07: Market segmentation by therapy
Part 08: Geographical segmentation
Part 09: Decision framework
Part 10: Drivers and challenges
Part 11: Market trends
Part 12: Vendor landscape
Part 13: Key vendor analysis
Part 14: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/7hhqct/global_castration
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets